Background: Antiviral treatment for chronic hepatitis B is costly, which presents challenges
for universal drug coverage for the estimated 480 000 people with the disease in Canada …

Background There is considerable variation in reimbursement policies in Asian countries
and this is likely to have an impact on treatment practice for chronic hepatitis B (CHB) …

Objectives: The main aims of this work were to describe patterns of medication use in the
treatment of chronic hepatitis B virus (HBV) infection in patients in the northern part of the …

Lamivudine is no longer recommended as first-line therapy for chronic hepatitis B. The same
advice has been made for adefovir and telbivudine, due to their relatively weak anti-viral …

Background In 2016, of the estimated 257 million people living with chronic hepatitis B virus
(HBV) infection worldwide, only a small proportion was diagnosed and treated. The …

Chronic hepatitis B virus disproportionately affects migrant communities in high-income
countries, reflecting increased migration from sub-Saharan Africa. Chronic hepatitis B virus …

Background: Guidelines have been devised to direct the care of patients with CHB but data
on the application of these guidelines, especially in primary care settings, has been limited …

Background Seven drugs are licensed for the treatment of chronic hepatitis B (CHB) in the
United Kingdom. Which initial treatment, secondary therapy, and whether antivirals should …

Abstract Background & Aims While universal screening of hepatitis B virus (HBV) is
recommended in high burden countries, little is known about the proportion of HBV‐infected …

Objective: To compare pharmacotherapy adherence, persistence, and healthcare
utilization/costs among US patients with chronic hepatitis B (CHB) initiated on an oral …